KR20090131766A - Cosmetics composition for skin whitening - Google Patents

Abstract

PURPOSE: A skin whitening cosmetic composition containing S-allylcysteine is provided to suppress melanogenesis and pigmentation. CONSTITUTION: A composition for suppressing melanogenesis contains 0.0001~10 weight% of S-allylcysteine as an active ingredient. The S-allylcysteine is more than 48% of suppression rate of melanogenesis. A skin whitening cosmetic composition contains 0.0001~10 weight% of S-allylcysteine as an active ingredient. The S-allylcysteine is denoted by chemical formula 1. The skin whitening cosmetic composition is used in the form of lotion, emulsion, cream, essence, cosmetic ointment, or pack.

Description

Skin whitening cosmetic composition {COSMETICS COMPOSITION FOR SKIN WHITENING}

The present invention relates to a skin whitening cosmetic composition, and more particularly to a skin whitening cosmetic composition excellent in melanin production inhibitory effect, including S- allyl cysteine excellent effect as a blemish, freckles improvement and skin lightening agent as an active ingredient.

It is everyone's constant desire to have white, fair skin. Human skin color is genetically determined by the concentration and distribution of melanin in the skin, and is also influenced by environmental or physiological conditions such as solar ultraviolet light, fatigue and stress. Melanin is a type of amino acid tyrosine (tyrosine) enzymes called tyrosinase (tyrosinase) acts to convert to dopa (DOPA), dopaquinone (dopaquinone) is produced through a non-enzymatic oxidation reaction.

However, although the pathway by which melanin is made is known, it is still not clear what mechanisms induce melanin synthesis, the previous step in which tyrosinase works.

Therefore, conventionally, a substance having a tyrosinase inhibitory activity such as hydroquinone, ascorbic acid, kojic acid, glutathione, and the like is combined with an ointment or a cosmetic, and the skin is whitened or stained. It has been used for the purpose of improving freckles. However, in the case of the above method, the use of the method is limited because it causes skin irritation or poor product stability, and thus the effect thereof is also weak.

In addition, many whitening agents known to date have been limited in use due to problems in toxicity and stability.

In order to solve the problems of the prior art, the present invention is to provide a composition for inhibiting melamine production is very excellent in the ability to inhibit the melamine production of the cultured melanoma cells.

The present invention also provides an excellent skin whitening cosmetic composition containing S-allyl cysteine as an active ingredient and excellent in inhibiting melamine production.

The present invention provides a composition for inhibiting melamine production comprising S-allyl cysteine as an active ingredient.

The S-allyl cysteine preferably contains 0.0001 to 10% by weight based on the total composition. The S-allylcysteine may have a melanin production inhibition rate of at least 48% or more, preferably 48% to 90%.

In addition, the present invention provides a skin whitening cosmetic composition comprising S- allyl cysteine as an active ingredient.

The S-allyl cysteine may include 0.0001 to 10% by weight based on the total cosmetic composition. In addition, the formulation of the skin whitening cosmetic composition may be any one selected from the group consisting of lotion, emulsion, cream, essence, cosmetic ointment and pack.

Hereinafter, the present invention will be described in detail.

The present inventors conducted a study to develop a new whitening agent, S-allyl cysteine (S-2-propenyl-cystein, C ₆ H ₁₁ NO ₂ S, Mw 161.22, mp 219-220, CAS represented by the following formula 1) No. 21593-77-1) was found to have no toxicity, good stability, and excellent whitening effect, thus completing the present invention.

[Formula 1]

That is, the anticancer effect and the antioxidant activity of the S-allylcysteine on melanoma cells are well known. However, the present invention was to develop a new whitening agent for a variety of substances using the mouse melanoma cells (B16 mouse melanoma cells) that can be screened to a substance that inhibits melanin synthesis induction itself. As a result, it was found that S-allylcysteine has a very strong melanin production inhibitory effect and a whitening effect. The whitening effect of the present invention is different from the conventional whitening effect of inhibiting the melanin synthesis ability of the cells in the cell differentiation, not the anti-cancer effect of inhibiting the cell differentiation of B16 melanoma cells.

Therefore, the present invention can provide a composition for inhibiting melamine production comprising S-allyl cysteine as an active ingredient.

In this case, the S-allyl cysteine preferably contains 0.0001 to 10% by weight based on the total composition. At this time, when the amount of S-allyl cysteine is more than 10% by weight, the stability is lowered during the preparation of the composition, when less than 0.0001% by weight, the effect is insignificant, so the whitening effect is not seen. For example, when added to an aqueous arbutin solution such that the final concentration of S-allylcysteine is 0.1 to 20 mg / ml, it exhibits at least 48% or more melanogenesis inhibition rate against B-16 melanoma cells, preferably 48 Melanogenesis inhibition rate of% to 90% is shown.

In addition, the present invention is characterized in that the S-allyl cysteine having the whitening effect is added to the cosmetic composition as an active ingredient to provide a skin whitening cosmetic composition.

The S-allyl cysteine is preferably used in an amount of 0.0001 to 10% by weight based on the total cosmetic composition. In this case, when the amount of S-allyl cysteine is more than 10% by weight, the stability of the composition is inferior, and if it is less than 0.0001% by weight, its action is insignificant, which is not preferable.

The formulation of the skin whitening cosmetic composition of the present invention is not particularly limited, but preferably any one formulation selected from the group consisting of lotion, milky lotion, cream, essence, cosmetic ointment and pack.

In addition, since the components of each of the formulations are well known in the art to which the present invention pertains, a detailed description thereof will be omitted.

In addition, the production method of the skin whitening cosmetic composition of the present invention can also be produced by a conventional method, the method is not specifically limited.

The present invention can provide a cosmetic composition excellent in inhibiting melanin production by effectively inhibiting pigmentation by adding S-allyl cysteine as an active ingredient to be used as an effective ingredient to improve freckles and freckles and skin lightening.

Hereinafter, preferred preparation examples and experimental examples are provided to help the understanding of the present invention, but the following examples are merely to illustrate the present invention, and the scope of the present invention is not limited to the following examples.

Experimental Example  One

S-allyl cysteine was added at a final concentration of 0.1 mg / ml, 1 mg / ml, 5 mg / ml, 20 mg / ml, and added to the culture medium of B-16 melanoma cells with an arbutin aqueous solution, respectively, and incubated for 3 days. Then, cells were trypsin-treated and removed from the culture vessel, centrifuged, and melanin was extracted. 1 ml of sodium hydroxide solution (1N concentration) was added thereto, and the mixture was boiled for 10 minutes to dissolve the melanin, and the absorbance was measured at 400 nanometers (nm) using a spectrophotometer to measure the amount of melanin produced. The melanin amount was measured by the absorbance of the unit cell allowance (10 ⁶ cells). The relative melanin production relative to the control group was calculated as the inhibition rate (%) and the results are summarized in Table 1. In addition, the experiment was repeated three times, S-allyl cysteine used in the experimental example was evaluated by purchasing 99% of samples from ChromaDex (USA).

TABLE 1

Inhibitory effect of melanin production at the cellular level

sample Melanin production % Inhibition Control group (no addition) 0.060 ± 0.002 - Control group 1: Arbutin (final concentration 200 mg / ml) 0.034 ± 0.001 44% S-allyl cysteine (final concentration 0.1 mg / ml) 0.031 ± 0.001 48% S-allyl cysteine (final concentration 1 mg / ml) 0.026 ± 0.001 57% S-allyl cysteine (final concentration 5 mg / ml) 0.020 ± 0.001 67% S-allyl cysteine (final concentration 20 mg / ml) 0.006 ± 0.001 90%

As can be seen from the results of Table 1, S-allylcysteine has a superior melanin production inhibitory ability against the cultured mouse melanoma cells compared to the known whitening agent Arbutin (Arbutin).

Example  1 and Comparative example  One

A skin external ointment containing S-allyl cysteine was prepared according to the following prescription example. In addition, external ointments were prepared using L-cysteine for comparison with S-allylcysteine.

TABLE 2

Classification (% by weight) Example 1 Comparative Example 1 S-allylcysteine L-cysteine diethyl sebacate brazing polyoxyethylene oleyl ether phosphate sodium benzoate petroleum jelly 1-8 5 6 Drops to 100 -1 8 5 6 Drops to 100

Example  2 and Comparative example  2

A cream in cosmetics containing S-allyl cysteine was prepared according to the following prescription example. In addition, external ointments were prepared using L-cysteine for comparison with S-allylcysteine.

TABLE 3

Division (weight%) Example 2 Comparative Example 2 S-allyl cysteine L-cysteine stearic acid cetanol potassium hydroxide glycerine propylene glycol preservative flavored purified water 0.5-15.0 1.0 0.7 5.0 3.0 Proper quantity to 100 -0.5 15.0 1.0 0.7 5.0 3.0 Correct Volume to 100

Example  3 and Comparative example  3

Soft cosmetics in the cosmetic containing S- allyl cysteine was prepared according to the following prescription example. In addition, external ointments were prepared using L-cysteine for comparison with S-allylcysteine.

TABLE 4

Division (weight%) Example 3 Comparative Example 3 S-allyl cysteine L-cysteine ethanol polylauric acid polyoxyethylene sorbitan paraoxybenzoic acid methyl glycerin 1,3-butylene glycol flavored water 0.2-10.0 1.0-0.2 5.0 6.0 Proper titration to 100 -0.2 10.0 1.0-0.2 5.0 6.0 Proper amount to 100

Example  4 and Comparative example  4

Nutritional longevity in the cosmetic containing S- allyl cysteine was prepared according to the following prescription example. In addition, external ointments were prepared using L-cysteine for comparison with S-allylcysteine.

TABLE 5

Division (weight%) Example 4 Comparative Example 4 S-allyl cysteine L-cysteine Waselin sesquioleate sorbitan polyoxyethylene oleyl ethyl paraoxybenzoic acid methyl propylene glycol ethanol carboxyvinyl polymer potassium hydroxide pigmented purified water 0.1-2.0 0.8 1.2 appropriate 5.0 3.2 18.0 0.1 appropriate volume to 100 -0.1 2.0 0.8 1.2 Accurate 5.0 3.2 18.0 0.1 Accurate to 100

Example  5 and Comparative example  5

A pack of cosmetics containing S-allylcysteine was prepared according to the following prescription example. In addition, external ointments were prepared using L-cysteine for comparison with S-allylcysteine.

TABLE 6

Division (weight%) Example 5 Comparative Example 5 S-allyl cysteine L-cysteine Glycerine Propylene glycol Polyvinyl alcohol Ethanol Polyoxyethylene Oleylethyl Paraoxybenzoic acid Methyl pigment Flavored water 0.2-5.0 4.0 15.0 8.0 1.0 0.2 Proper quantity to 100 -0.2 5.0 4.0 15.0 8.0 1.0 0.2 Proper quantity to 100

Example  6 and Comparative example  6

Assets in the cosmetic composition containing S-allyl cysteine were prepared according to the following prescription example. In addition, external ointments were prepared using L-cysteine for comparison with S-allylcysteine.

TABLE 7

Division (weight%) Example 6 Comparative Example 6 S-allyl cysteine L-cysteine propylene glycol glycerin sodium hyaluronate aqueous solution (1%) ethanol polyoxyethylene cured castor oil paraoxybenzoic acid purified water 0.5-10.0 10.0 5.0 5.0 1.0 0.1 dose to 100 -0.5 10.0 10.0 5.0 5.0 1.0 0.1 dose to 100

Experimental Example

20 healthy males and females were placed in the lower hips of each arm with 6 holes of 7 mm diameter in two rows of aluminum foil, and 60mJ / cm ² light was irradiated using ORIEL solar simulator 1000W at a distance of 10cm from the arm. . The irradiation site was washed well with 70% ethanol aqueous solution before irradiation. The bases prepared according to Example 1-6 and Comparative Example 1-6 were applied to the same row twice a day from 3 days before irradiation to 3 weeks after irradiation. At this time, the pack formulation of Example 6 and Comparative Example 6 was removed 15 minutes after the application.

For each, the degree of pigmentation was visually determined and the degree to which the pigmentation was suppressed compared to the comparative example was evaluated in two stages of effective and no effect, and the results are shown in Table 8.

TABLE 8

Pigmentation Inhibitory Effects of Ointments and Cosmetics Containing S-Allylcysteine

Experimental substance Effective (persons) No effect (persons) Example 1 15 5 Example 2 16 6 Example 3 12 8 Example 4 12 8 Example 5 12 8 Example 6 14 6

As can be seen from the results in Table 8 above, ointments and cosmetics containing S-allylcysteine prepared according to Example 1-6 were relatively at least 12 or more out of 20 subjects compared to Comparative Examples 1-6. It showed a whitening effect against, and did not show any side effects in the skin. Therefore, it can be seen that the S-allyl cysteine according to the present invention is a safe and very effective effect of blemishes and freckles or skin whitening agents.

Claims (6)

Melamine production inhibition composition comprising S- allyl cysteine as an active ingredient. The composition for inhibiting melamine production according to claim 1, wherein the S-allylcysteine comprises 0.0001 to 10% by weight based on the total composition. The composition for inhibiting melamine production according to claim 1, wherein the S-allylcysteine has a melanin production inhibition rate of at least 48% or more. Skin whitening cosmetic composition comprising S-allyl cysteine as an active ingredient. The skin whitening cosmetic composition of claim 4, wherein the S-allylcysteine comprises 0.0001 to 10% by weight based on the total cosmetic composition. The skin whitening cosmetic composition according to claim 4, wherein the skin whitening cosmetic composition is any one selected from the group consisting of lotion, milky lotion, cream, essence, cosmetic ointment, and a pack.